This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Alexion's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Alexion Pharmaceuticals, Inc. (ALXN)

Q1 2012 Results Earnings Call

April 24, 2012 10:00 AM ET


Leonard Bell – Chief Executive Officer

Steve Squinto – Executive Vice President and Head, R&D

Vikas Sinha – Senior Vice President and CFO

David Hallal – Senior Vice President, Global Commercial Operations

Tom Dubin – Senior Vice President and Chief Legal Officer


Rachel McMinn – Bank of America-Merrill Lynch

Eric Schmidt – Cowen and Company

Geoff Meacham – JPMorgan

Yogesh Ahuja – Goldman Sachs

Salveen Richter – Canaccord

Ying Huang – Barclays

Robyn Karnauskas – Deutsche Bank

Matt Roden – UBS

Howard Liang – Leerink Swann

Art – Sanford Bernstein



Good day, ladies and gentlemen. And welcome to the First Quarter 2012 Alexion Pharmaceuticals’ Earnings Conference Call. My name is [Alisha], and I’ll be your operator for today. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. (Operator Instructions)

As a reminder, this conference is being recorded for replay purposes. I would now like to introduce your host for today’s call, Dr. Leonard Bell, Chief Executive Officer. Please proceed, sir.

Leonard Bell

Thank you, [Alisha]. Good morning. Thank you for joining us on today’s call to discuss Alexion’s performance for the first quarter of 2012. I’m joined by members of Alexion management. Steve Squinto, Executive Vice President and Head of R&D; Vikas Sinha, Senior Vice President and Chief Financial Officer; David Hallal, Senior Vice President, Global Commercial Operations; and Tom Dubin, Senior Vice President and Chief Legal Officer. We also welcome our entire Alexion team working around the world.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs